Literature DB >> 14983037

An anti-CD45RO immunotoxin kills HIV-latently infected cells from individuals on HAART with little effect on CD8 memory.

J Saavedra-Lozano1, Y Cao, J Callison, R Sarode, D Sodora, J Edgar, J Hatfield, L Picker, D Peterson, O Ramilo, E S Vitetta.   

Abstract

CD4+ CD45RO+ T cells are the major latent viral reservoir in HIV-infected individuals and hence a major obstacle in curing the disease. An anti-CD45RO immunotoxin (IT) can decrease the number of both productively and latently infected CD4+ T cells obtained from HIV-infected individuals with detectable viremia. In this study, we determined whether this IT could also kill latently infected replication-competent CD4+ T cells obtained from infected individuals without detectable plasma viremia. Our results demonstrate that ex vivo treatment with the anti-CD45RO IT significantly reduced the frequency of these cells. In contrast, the IT had only a modest effect on the cytomegalovirus-specific memory responses of CD8+ T cells. These results suggest that purging latent cells from infected individuals on highly active antiretroviral therapy with the anti-CD45RO IT might reduce the HIV latent reservoir without seriously compromising CD8+ T cell memory responses.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14983037      PMCID: PMC356978          DOI: 10.1073/pnas.0308381100

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  37 in total

1.  HIV-1 and HAART: a time to cure, a time to kill.

Authors:  M S Saag; J M Kilby
Journal:  Nat Med       Date:  1999-06       Impact factor: 53.440

2.  Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy.

Authors:  D Finzi; J Blankson; J D Siliciano; J B Margolick; K Chadwick; T Pierson; K Smith; J Lisziewicz; F Lori; C Flexner; T C Quinn; R E Chaisson; E Rosenberg; B Walker; S Gange; J Gallant; R F Siliciano
Journal:  Nat Med       Date:  1999-05       Impact factor: 53.440

3.  Design and analysis of serial limiting dilution assays with small sample sizes.

Authors:  C Macken
Journal:  J Immunol Methods       Date:  1999-01-01       Impact factor: 2.303

4.  The GLP large scale preparation of immunotoxins containing deglycosylated ricin A chain and a hindered disulfide bond.

Authors:  V Ghetie; P Thorpe; M A Ghetie; P Knowles; J W Uhr; E S Vitetta
Journal:  J Immunol Methods       Date:  1991-09-13       Impact factor: 2.303

5.  Randomized, controlled phase II trial of subcutaneous interleukin-2 in combination with highly active antiretroviral therapy (HAART) in HIV patients.

Authors:  U R Hengge; M Goos; S Esser; V Exner; H Dötterer; H Wiehler; C Borchard; K Müller; A Beckmann; M T Eppner; A Berger; M Fiedler
Journal:  AIDS       Date:  1998-12-03       Impact factor: 4.177

6.  Fitting limiting dilution experiments with generalized linear models results in a test of the single-hit Poisson assumption.

Authors:  T Bonnefoix; P Bonnefoix; P Verdiel; J J Sotto
Journal:  J Immunol Methods       Date:  1996-08-14       Impact factor: 2.303

7.  Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection.

Authors:  T W Chun; L Carruth; D Finzi; X Shen; J A DiGiuseppe; H Taylor; M Hermankova; K Chadwick; J Margolick; T C Quinn; Y H Kuo; R Brookmeyer; M A Zeiger; P Barditch-Crovo; R F Siliciano
Journal:  Nature       Date:  1997-05-08       Impact factor: 49.962

8.  Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy.

Authors:  T W Chun; L Stuyver; S B Mizell; L A Ehler; J A Mican; M Baseler; A L Lloyd; M A Nowak; A S Fauci
Journal:  Proc Natl Acad Sci U S A       Date:  1997-11-25       Impact factor: 11.205

9.  Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy.

Authors:  L Zhang; B Ramratnam; K Tenner-Racz; Y He; M Vesanen; S Lewin; A Talal; P Racz; A S Perelson; B T Korber; M Markowitz; D D Ho
Journal:  N Engl J Med       Date:  1999-05-27       Impact factor: 91.245

10.  Biological and biochemical characterization of a cloned Leu-3- cell surviving infection with the acquired immune deficiency syndrome retrovirus.

Authors:  T M Folks; D Powell; M Lightfoote; S Koenig; A S Fauci; S Benn; A Rabson; D Daugherty; H E Gendelman; M D Hoggan
Journal:  J Exp Med       Date:  1986-07-01       Impact factor: 14.307

View more
  6 in total

1.  Loss of naïve (CD45RA+) CD4+ lymphocytes during pediatric infection with feline immunodeficiency virus.

Authors:  Abigail D Carreño; Ayalew Mergia; Janelle Novak; Nazareth Gengozian; Calvin M Johnson
Journal:  Vet Immunol Immunopathol       Date:  2007-09-11       Impact factor: 2.046

Review 2.  Passive and active vaccination strategies to prevent ricin poisoning.

Authors:  Seth H Pincus; Joan E Smallshaw; Kejing Song; Jody Berry; Ellen S Vitetta
Journal:  Toxins (Basel)       Date:  2011-09-15       Impact factor: 4.546

Review 3.  Latency: the hidden HIV-1 challenge.

Authors:  Alessandro Marcello
Journal:  Retrovirology       Date:  2006-01-16       Impact factor: 4.602

4.  Targeted killing of virally infected cells by radiolabeled antibodies to viral proteins.

Authors:  Ekaterina Dadachova; Mahesh C Patel; Sima Toussi; Christos Apostolidis; Alfred Morgenstern; Martin W Brechbiel; Miroslaw K Gorny; Susan Zolla-Pazner; Arturo Casadevall; Harris Goldstein
Journal:  PLoS Med       Date:  2006-11       Impact factor: 11.069

5.  Expression of the memory marker CD45RO on helper T cells in macaques.

Authors:  Michael Valentine; Kejing Song; Grace A Maresh; Heather Mack; Maria Cecilia Huaman; Patricia Polacino; On Ho; Anthony Cristillo; Hye Kyung Chung; Shiu-Lok Hu; Seth H Pincus
Journal:  PLoS One       Date:  2013-09-04       Impact factor: 3.240

Review 6.  Immunotoxins constructed with ribosome-inactivating proteins and their enhancers: a lethal cocktail with tumor specific efficacy.

Authors:  Roger Gilabert-Oriol; Alexander Weng; Benedicta von Mallinckrodt; Matthias F Melzig; Hendrik Fuchs; Mayank Thakur
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.